Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6436 AL 6450

Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains

Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, Zhu HQ, Zhang QQ, Zhang YD, Xu J.

Brain Res. 2011 Jan 12;1368:239-47. doi: 10.1016/j.brainres.2010.10.053. Epub 2010 Oct 21.

Video-based coping skills to reduce health risk and improve psychological and physical well-being in Alzheimer's disease family caregivers

Williams VP, Bishop-Fitzpatrick L, Lane JD, Gwyther LP, Ballard EL, Vendittelli AP, Hutchins TC, Williams RB.

Psychosom Med. 2010 Nov;72(9):897-904. doi: 10.1097/PSY.0b013e3181fc2d09. Epub 2010 Oct 26.

[Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)]

Agüera-Ortiz LF; Grupo de Investigadores del Estudio MEMORY.

Rev Neurol. 2010 Nov 1;51(9):525-34.

Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease

Kayed R.

Hum Vaccin. 2010 Nov;6(11):931-5. doi: 10.4161/hv.6.11.12689. Epub 2010 Nov 1.

α-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential

Lichtenthaler SF.

J Neurochem. 2011 Jan;116(1):10-21. doi: 10.1111/j.1471-4159.2010.07081.x. Epub 2010 Dec 2.

Switching cholinesterase inhibitors in older adults with dementia

Massoud F, Desmarais JE, Gauthier S.

Int Psychogeriatr. 2011 Apr;23(3):372-8. doi: 10.1017/S1041610210001985. Epub 2010 Nov 3.

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS.

JAMA. 2010 Nov 3;304(17):1903-11. doi: 10.1001/jama.2010.1510.

Potential therapeutic agents against Alzheimer's disease from natural sources

Park SY.

Arch Pharm Res. 2010 Oct;33(10):1589-609. doi: 10.1007/s12272-010-1010-y. Epub 2010 Oct 30.

A meta-analysis of mood stabilizers for Alzheimer's disease

Xiao H, Su Y, Cao X, Sun S, Liang Z.

J Huazhong Univ Sci Technolog Med Sci. 2010 Oct;30(5):652-8. doi: 10.1007/s11596-010-0559-5. Epub 2010 Nov 10.

Natural products as a source of Alzheimer's drug leads

Williams P, Sorribas A, Howes MJ.

Nat Prod Rep. 2011 Jan;28(1):48-77. doi: 10.1039/c0np00027b. Epub 2010 Nov 12.

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease

Panza F, Frisardi V, Imbimbo BP, D'Onofrio G, Pietrarossa G, Seripa D, Pilotto A, Solfrizzi V.

Immunotherapy. 2010 Nov;2(6):767-82. doi: 10.2217/imt.10.80.

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial

Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR.

J Clin Psychopharmacol. 2010 Dec;30(6):683-7. doi: 10.1097/jcp.0b013e3181fa05bb.

Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease

Lannfelt L, Pettersson FE, Nilsson LN.

Nutr Rev. 2010 Dec;68 Suppl 2:S128-34. doi: 10.1111/j.1753-4887.2010.00347.x.

Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment

Korabecny J, Musilek K, Holas O, Nepovimova E, Jun D, Zemek F, Opletalova V, Patocka J, Dohnal V, Nachon F, Hroudova J, Fisar Z, Kuca K.

Molecules. 2010 Dec 2;15(12):8804-12. doi: 10.3390/molecules15128804.

Roles of β-adrenergic receptors in Alzheimer's disease: implications for novel therapeutics

Yu JT, Wang ND, Ma T, Jiang H, Guan J, Tan L.

Brain Res Bull. 2011 Feb 1;84(2):111-7. doi: 10.1016/j.brainresbull.2010.11.004. Epub 2010 Dec 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias